The immune system is a constant guardian of our body; its versatility allows it not only to defend us from bacteria and viruses but also to monitor the appearance of abnormal cells that, if left unchecked, can turn into cancer. Within this complex network, Toll-like receptors (TLRs) play a fundamental role by acting as sensors capable of recognizing signals from microorganisms or tissue damage and, in consequence, activating one or more signaling cascades that culminate in the production of cytokines (messenger molecules that enable communication between immune cells).

The article by Patra, Shah, and Choi (2020), published in Seminars in Cancer Biology, explains how TLR-induced cytokines represent a true “double-edged sword.” On the one hand, they can trigger powerful antitumor responses, but on the other, under conditions of dysregulation, they can contribute to chronic inflammation, autoimmune diseases, and cancer progression. This ambivalence is best understood through the concept of cancer immunoediting, a dynamic process in which the immune system first eliminates malignant cells, then keeps resistant survivors in balance, and finally allows some to escape and progress in an immunosuppressive tumor microenvironment.

Several concrete examples illustrate this paradox. TNF-α (tumor necrosis factor alpha) was initially described for its ability to destroy cancer cells. However, when its production is persistent, it stimulates inflammatory pathways that protect tumors from apoptosis and promote the formation of new blood vessels. In simple terms, this happens because TNF-α activates survival signals inside the tumor that make the cancer cells harder to kill, while also stimulating the growth of blood vessels that “feed” the tumor with nutrients. This discovery made it clear that blocking TNF-α with monoclonal antibodies such as infliximab or adalimumab can help in the treatment of autoimmune diseases like rheumatoid arthritis or Crohn’s disease. Yet it also poses a dilemma: by inhibiting it, patients become more vulnerable to infections, which highlights how delicate it is to modulate these molecules.

IL-6 is another “two-faced” cytokine. On the one hand, it can mobilize lymphocytes to attack tumors, but when produced chronically, it fuels the proliferation of malignant cells, encourages angiogenesis, and helps cancer evade the immune system. This happens because IL-6 not only sends growth signals directly to cancer cells but also reshapes the environment around the tumor to favor its expansion and survival. For this reason, drugs such as tocilizumab, an antibody against its receptor, are already used in autoimmune diseases and are being evaluated in oncology as a strategy to “take away fuel” from the tumor.

IL-1β and IL-18, activated by the inflammasome, are essential in acute inflammation; the first promotes fever and intense inflammation, while the second boosts the activity of T lymphocytes and NK cells. However, when produced in excess, they aggravate inflammatory and autoimmune diseases. Mechanistically, this occurs because their constant signaling keeps the immune system in a state of “over-alert,” attacking even when no real external threat is present. Drugs like anakinra, an IL-1 receptor antagonist, and new antibodies against IL-18 show how molecular knowledge can translate into specific therapies.

IL-8 also deserves attention. This chemokine attracts neutrophils to infection sites, which is fundamental for controlling microbes. However, chronically high levels of IL-8 can damage healthy tissues, as seen in cystic fibrosis, or favor tumors like colorectal cancer by stimulating invasion and angiogenesis. In simple terms, IL-8 acts like a “beacon” that constantly calls immune cells into action. When this beacon never turns off, the result is tissue damage or an environment where tumors take advantage of the continuous cell traffic to grow and spread. Currently, neutralizing antibodies such as BMS-986253 are being studied, which could help reduce inflammation and also limit tumor progression.

Even type I interferons, considered heroes for their ability to block viral infections and enhance antitumor responses, show their dark side. In diseases such as lupus, sustained production of IFN-α or IFN-β activates the immune system in an uncontrolled way against the body itself. This happens because interferons, which normally act as a powerful alarm system during infections, remain switched on even in the absence of viruses, tricking the immune system into attacking healthy tissues. This has led to the development of innovative therapies, such as anifrolumab, an antibody against the interferon receptor, which has already shown encouraging results in clinical trials for lupus.

Figure 1. Cytokines induced by Toll-like receptors show a dual nature. In balance, molecules such as TNF-α, IL-6, IL-1β, IL-18, IL-8, and type I interferons activate immune defenses against infections and tumors. When dysregulated, the same signals sustain chronic inflammation, trigger autoimmunity, and promote cancer progression.

What the authors emphasize is that TLRs and associated cytokines are central nodes in immunity. Their modulation opens therapeutic opportunities in two opposite yet complementary directions: stimulating the immune response against cancer and dampening inflammation in autoimmune diseases. The examples of TNF-α, IL-6, IL-1β, IL-8, and interferons illustrate how the same molecule can be an ally or an enemy depending on the context.

The challenge of modern medicine is to find the right balance between boosting immunity when cancer needs to be fought and, at the same time, preventing excessive inflammation from damaging healthy tissues or feeding tumors. Research in TLR-induced cytokine-based immunotherapy is showing that this balance is possible. Thanks to recent advances in immuno-oncology, we are moving closer to increasingly specific and personalized therapies, capable of harnessing the power of the immune system without unleashing its harmful consequences.

Ultimately, recognizing the protective and destructive power of the immune system allows us to design smarter treatments, aimed at directing the “fire” of immunity with precision. Maintaining this delicate balance not only represents the future of immunotherapy but also a real hope for millions of patients around the world.

Main Reference:

Patra, M. C., Shah, M., & Choi, S. (2020). Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases. Seminars in cancer biology, 64, 61–82. https://doi.org/10.1016/j.semcancer.2019.05.002

Other References:

Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004). The three Es of cancer immunoediting. Annual review of immunology, 22, 329–360. https://doi.org/10.1146/annurev.immunol.22.012703.104803

Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014). New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Current opinion in immunology, 27, 16–25. https://doi.org/10.1016/j.coi.2014.01.004

Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., Signori, E., Honoki, K., Georgakilas, A. G., Amin, A., Helferich, W. G., Boosani, C. S., Guha, G., Ciriolo, M. R., Chen, S., Mohammed, S. I., … Kwon, B. S. (2015). Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Seminars in cancer biology, 35 Suppl, S185–S198. https://doi.org/10.1016/j.semcancer.2015.03.004